EMAS position statement: Managing the menopause in women with a past history of endometriosis

Introduction: Endometriosis is a common disease in women of reproductive age. The symptoms usually disappear after a natural or a surgical menopause. Estrogen-based hormone therapy is required in women with premature or early menopause until the average age of the natural menopause and should be considered in older women with severe climacteric symptoms. However use of hormone therapy raises concerns about disease recurrence with pain symptoms, need for surgery and possibly malignant transformation of residual endometriosis

EMAS position statement: managing obese postmenopausal women.

Obesity is a public health problem, with overweight individuals representing approximately 20% of the adult world population. Postmenopausal status is associated with higher prevalence of obesity, as 44% of postmenopausal women are overweight, among whom 23% are obese. Obesity often co-exists with other diseases, the most important being diabetes mellitus, dyslipidemia and hypertension. Furthermore, obesity increases the risk of gynecologic cancer, cardiovascular disease, venous thromboembolism, osteoarthritis and chronic back pain.Consensus Development ConferenceJournal Articleinfo:eu-repo/semantics/publishe

EMAS position statement: managing the menopause in women with epilepsy.

Epilepsy is a major public health problem worldwide which is clinically characterized by recurrent seizures.Consensus Development ConferenceJournal ArticleReviewinfo:eu-repo/semantics/publishe

EMAS position statement: Managing the menopause in the context of coronary heart disease.

Cardiovascular disease (CVD) including coronary heart disease (CHD) and stroke is the most common cause of female death. Premenopausal CHD is very rare but when women enter the menopause the incidence of CHD increases markedly. CHD presents 10 years later in women than in men. The reason is still unclear but the protective effects of estrogens have been suggested.Journal ArticlePractice Guidelineinfo:eu-repo/semantics/publishe

EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis.

Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.Journal ArticleReviewSCOPUS: ar.jinfo:eu-repo/semantics/publishe

EMAS position statement: Vitamin D and postmenopausal health

Introduction: There is emerging evidence on the widespread tissue effects of vitamin D

EMAS position statement: Bone densitometry screening for osteoporosis.

Osteoporosis and its consequent fractures is a major public health problem.Journal ArticlePractice Guidelineinfo:eu-repo/semantics/publishe

EMAS position statement: Vitamin D and postmenopausal health.

There is emerging evidence on the widespread tissue effects of vitamin D.Journal ArticleSCOPUS: ar.jinfo:eu-repo/semantics/publishe

EMAS position statement: Managing the menopause in women with a past history of endometriosis.

Endometriosis is a common disease in women of reproductive age. The symptoms usually disappear after a natural or a surgical menopause. Estrogen-based hormone therapy is required in women with premature or early menopause until the average age of the natural menopause and should be considered in older women with severe climacteric symptoms. However use of hormone therapy raises concerns about disease recurrence with pain symptoms, need for surgery and possibly malignant transformation of residual endometriosis.Consensus Development ConferenceJournal ArticlePractice GuidelineSCOPUS: re.jinfo:eu-repo/semantics/publishe

EMAS position statement: Managing women with premature ovarian failure.

Premature ovarian failure (also known as premature menopause) is defined as menopause before the age of 40. It can be "natural" or "iatrogenic" such as after bilateral oophorectomy. It may be either primary or secondary. In the majority of cases of primary POF the cause is unknown. Chromosome abnormalities (especially X chromosome), follicle-stimulating hormone receptor gene polymorphisms, inhibin B mutations, enzyme deficiencies and autoimmune disease may be involved. Secondary POF is becoming more important as survival after treatment of malignancy through surgery, radiotherapy and chemotherapy continues to improve.Journal ArticlePractice Guidelineinfo:eu-repo/semantics/publishe